CRLX101: Phase II data

Cerulean reported data from 18 patients with platinum-resistant ovarian cancer in the first stage of an open-label, U.S. Phase II trial showing that 15 mg/m 2

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE